BioNTech’s BNT111 phase 2 clinical trial makes progress as patient with advanced Melanoma treated

GERMANY – BioNTech, a German pharmaceutical company, has announced that the first patient has been treated in its BNT111 phase 2 cancer medication trial. Currently, the study is evaluating the Company’s therapeutic cancer vaccine candidate BNT111 in combination with Libtayo (cemiplimab), an anti-PD-1 monoclonal antibody, in patients with anti-PD1-refractory/relapsed unresectable Stage III or IV melanoma. Melanoma is a type of skin cancer that develops when melanocytes (the cells that give the skin its tan or brown color) start to grow out of control or can be refereed to hyperpigmentation. BNT111…

Read More

CureVac’s vaccine proves to have a 47% efficacy rating after its preliminary results

EUROPE – The German company CureVac provided disappointing preliminary results from a clinical trial of its COVID-19 vaccine, dimming hopes that it could help fill the world’s current greatest need. The trial, which included 40,000 volunteers in Latin America and Europe, estimated that CureVac’s mRNA vaccine had an efficacy of just 47 percent, among the lowest reported so far from any COVID-19 vaccine maker. Results released were based on data from 135 volunteers who got sick with COVID-19 as an independent panel compared the number of sick people who had…

Read More

GAVI receives US $28.9 million from KFW Development Bank to boost routine vaccinations for children in EAC

EAST AFRICA – KfW has given US $28.9 million on behalf of the German Federal Ministry for Economic Cooperation and Development (BMZ) to support GAVI, the Vaccine Alliance, in effectively protecting children in the East African Community (EAC) against infectious diseases. The funds will be used to facilitate the procurement of vaccines, consumables, transport and insurance on a pro rata basis. This funding comes as a follow up to the US $346.1 million kfW has issued to fund immunization programs in East Africa since 2013. The funds have made possible…

Read More

German legislature approves legislation that will expedite access to life-changing cell and gene therapies

GERMANY-The German parliament, the Bundestag, has approved a legislation that would enable patients have greater access to new transformative cell and gene therapies. The legislation will address a bureaucratic barrier that delayed the availabilities of new and innovative drugs, medical devices and procedures (NUB) to patients. In order to be able to integrate new examination and treatment methods into the G-DRG system, the NUB request procedure was first introduced in Germany in 2005. For this purpose, NUB requests (InEK) would only be made once in a year with the extra…

Read More

New research indicates masks are effective in mitigating spread of COVID-19

GERMANY- A research conducted by Chinese and German researchers has showed that masks are effective against spread of SARS-CoV-2 virus(severe acute respiratory syndrome coronavirus 2), the agent that causes corona virus disease 2019. The team, led by Hang Su of Max Planck Institute for Chemistry in Mainz has established that the efficacy of masks against the virus is dependent on the viral load in a given environment. In most environments, however, it was found that the abundance of the virus is low. Therefore, surgical masks which exhibit a variable range…

Read More